Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-776
Abstract: Background Outcomes for patients with relapsed/refractory (R/R) peripheral T-cell lymphomas (R/R-PTCLs) are poor. Single agent overall response rates (ORRs) for R/R-PTCLs generally fall within the 20-35% range, with a median progression-free survival (PFS) of less… read more here.
Keywords: chidamide group; mit group; lipo mit; group ... See more keywords